Is Lilly Stock’s Winning Streak Skill Or Luck?
Today’s big story: Anthropic IPO: Priced For 2031, Or 2036?
For questions about this article or underlying research, email help@trefis.com.
Eli Lilly (LLY) makes medicines, with Mounjaro and Zepbound accounting for most of its sales in the latest quarter. Its stock has beaten the S&P 500 in each of the last five years, measured in 12-month periods to November 2026. A record that steady looks like proof of an exceptional company. Of 488 large U.S. stocks, how many do you think did the same?

How Rare Is Lilly’s Winning Streak?
Measured before dividends and counted back from November 17, 2026, Lilly stock rose more than the S&P 500 in each of those five years.
| Period | The stock | S&P 500 |
|---|---|---|
| Nov 9, 2021 to Nov 9, 2022 | +38.6% | -20.0% |
| Nov 9, 2022 to Nov 10, 2023 | +64.5% | +17.8% |
| Nov 10, 2023 to Nov 12, 2024 | +37.0% | +35.5% |
| Nov 12, 2024 to Nov 14, 2025 | +25.2% | +12.5% |
| Nov 14, 2025 to Nov 17, 2026 | +38.1% | +9.0% |
Price changes over periods of 252 trading sessions each, dividends excluded.
Only 8 of the 488 current S&P 500 members measured did the same. Beating the index in a single year is far from certain. In the latest year, 54.7% of those stocks managed it, but in the twelve months to November 2025, only 32.0% did. So most stocks beat the index in some years and trail it in others, and doing it five years running is rare.
Could A Streak Like This Be Luck?
With this many stocks, a few will string together long streaks even if no company is any better than another. About four in ten of the stocks beat the index in a typical year of these five.
Now suppose it were pure luck which ones. Each year you put all 488 names in a hat and pull out 43.4% of them as that year’s winners. Do that five years in a row and about seven names come out every single time. Seven companies would have a five-year winning streak with no skill involved at all.
In fact, 8 companies have such a streak, barely more than the hat gives. A company or two among them may have a real edge. The share price alone cannot show which ones, or whether Lilly is one of them.
Did Lilly’s Profit Grow Through The Streak?
Mostly, yes: Lilly’s twelve-month profit rose in four of the five years of the streak, counting one-time items. Management said Mounjaro and Zepbound drove sales growth in fiscal Q3 2026.
Over the whole streak, Lilly’s profit grew 361.8%, while the stock rose 440.2%. The exception came in the year to November 2023. Twelve-month profit to September 2023 fell 17.3% from a year earlier, yet the stock still beat the index. So in most years of the streak, rising profit stood behind the rising share price. That is something you can check for yourself, not a ruling on skill.
What To Watch Instead Of The Streak
Lilly’s sales are still growing fast. Revenue rose 38.6% in fiscal Q3 2026 from a year earlier, and management raised its revenue forecast for the full year on the October 29, 2026 call. Management also said part of 2026’s revenue came from one-time items it does not expect to recur. These were mainly milestone payments and changes in estimates for rebates and discounts.
A streak only records what the share price did. The figure to watch instead is Lilly’s twelve-month profit growth, which Lilly next updates with its report due in February 2027.
Even a streak with rising profit behind it belongs to one company, and one company’s next report can surprise anyone. Owning a group of strong, profitable leaders instead of one leaves less riding on any single streak.
Why Own One Leader When You Can Own 30?
If you like finding quality companies like Eli Lilly, the Trefis High Quality (HQ) Portfolio holds 30 of them in equal weight, and has returned more than 105% since its September 2020 launch. You’re welcome to look inside.
Spot an error or want more like this? Tell us in 10 seconds.